Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients — Stella

Home/Non-small Cell Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Non-small Cell Lung Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Taiwan

Tri-Service General Hospital, Taipei

Key details

Phase

Early testing / Safety & dosing

Sponsor

Precision Biotech Taiwan Corp.

Collaborators

Tri-Service General Hospital

Enrollment target

~24 participants

Started

November 2020

Primary completion

December 2027

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

20 Years – 70 Years

Last updated February 2025